Reported Thursday, Pendopharm Partners With Ascendis Pharma For Exclusive Distribution Of TransCon PTH In Canada
Portfolio Pulse from Benzinga Newsdesk
Pendopharm has partnered with Ascendis Pharma for the exclusive distribution of TransCon™ PTH in Canada. Pendopharm will handle regulatory approval and commercialization of the hypoparathyroidism treatment. Financial terms were not disclosed.
July 05, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma has entered into a partnership with Pendopharm for the exclusive distribution of its hypoparathyroidism treatment, TransCon™ PTH, in Canada. Pendopharm will be responsible for regulatory approval and commercialization.
The partnership with Pendopharm for the distribution of TransCon™ PTH in Canada is likely to positively impact Ascendis Pharma's stock in the short term. The agreement expands Ascendis' market reach and potential revenue streams, although financial terms were not disclosed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80